Entity

Time filter

Source Type

Arlesheim, Switzerland

Protte K.,University of Hohenheim | Bollow C.,Solent GmbH & Co. KG | Sonne A.,Weleda AG | Menendez-Aguirre O.,University of Hohenheim | And 2 more authors.
Food Biophysics | Year: 2016

Stability of whey protein-pectin complexes is an essential criterion for their application in different food matrices. The impact of process parameters on micro- and macro-structural characteristics of thermally stabilised whey protein-pectin complexes was investigated using fluorescence spectroscopy, ζ-potential measurements, dynamic light scattering and phase separation. Complexes prepared from whey protein isolate (WPI) and pectins with different degrees of esterification (HMP, LMP) were generated at different biopolymer concentrations (WPI + pectin: 5.0 % + 1.0 %, chigh; 2.75 % + 0.55 %, cmed; 0.5 % + 0.1 %, clow), heating temperatures (80-90∘C) and pH levels (6.1-4.0). Micro- and macro-structural characteristics of the complexes depended on concentration level and degree of esterification, with complexes being more sensitive towards environmental changes at clow than at cmed and chigh. WPI-LMP complexes exhibited sizes <1 μm suitable for micro-encapsulation, whereas WPI-HMP complexes at cmed achieved sizes from 1-10 μm and at chigh from 10-200 μm underlining their potential as fat-replacers and structuring agents, respectively. Slopes and intercepts derived from intensity ratios of fluorescence spectra gave insights into the state of unfolding of β-lactoglobulin within the complexes and thus about the protective effect of pectin addition. © 2016 Springer Science+Business Media New York Source


Grundemann C.,Albert Ludwigs University of Freiburg | Papagiannopoulos M.,Weleda AG | Lamy E.,Albert Ludwigs University of Freiburg | Mersch-Sundermann V.,Albert Ludwigs University of Freiburg | Huber R.,Albert Ludwigs University of Freiburg
Phytomedicine | Year: 2011

Introduction: Gencydo®, a combination of lemon (Citrus limon) juice and aqueous quince (Cydonia oblonga) extract has been used traditionally in anthroposophical medicine for treating patients with allergic rhinitis or asthma. Because there are no reports about the mode of action, we investigated the anti-allergic effects of this preparation in vitro by using cell lines and primary cells in various biological and immunological endpoints. Materials and methods: The release of soluble mediators from basophilic cells, mast cells and lung epithelial cells, which are essential for the initiation of early- and late-phase allergic reactions, was analyzed in relation to the synthetic anti-allergic drugs azelastine and dexamethasone. In addition, the impact of Gencydo® on the viability and activation of GM-CSF-activated eosinophil granulocytes was investigated. Results and discussion: Gencydo® reduced the degranulation and histamine release of IgE-activated basophilic cells and mast cells and inhibited the IgE- and PMA/A23187-induced increases in IL-8, TNF-α and GM-CSF production in mast cells. The effects were comparable to that of the used concentration of azelastine and dexamethasone. Furthermore, Gencydo® partially blocked eotaxin release from human bronchial epithelial cells, but has no impact on the viability and activation of GM-CSF-activated eosinophil granulocytes. In conclusion, these results give a rational base for the topical use of Gencydo® in treatment of allergic disorders through the down regulation of soluble mediators, which are essential for the initiation and maintenance of allergic reactions. © 2010 Elsevier GmbH. All rights reserved. Source


Zimmermann B.F.,University of Bonn | Zimmermann B.F.,Institute Prof. Dr. Kurz GmbH | Woelwer-Rieck U.,University of Bonn | Papagiannopoulos M.,University of Bonn | Papagiannopoulos M.,Weleda AG
Food Analytical Methods | Year: 2012

Stevia rebaudiana Bertoni contains several steviol glycosides with sweet flavour. They all are sweeter than sucrose (up to factor 450). The various steviol glycosides are difficult to separate by reversed-phase chromatography. In this paper, five different hydrophilic liquid interaction chromatography columns are characterized using isocratic elution (5-20% water in acetonitrile with buffer or formic acid). Separation of the steviol glycosides is possible with all but one of the tested columns, but the robustness of the separation against changes of buffer concentration and percentage of water differ. Aqueous percentage and ion strength of the eluent are the main factors to be optimized in method development. © 2011 Springer Science+Business Media, LLC. Source


Furer K.,University of Basel | Furer K.,University of Zurich | Raith M.,University of Basel | Brenneisen R.,University of Bern | And 5 more authors.
Planta Medica | Year: 2013

Bryophyllum pinnatum is a succulent perennial plant native to Madagascar which is used in anthroposophical medicine to treat psychiatric disorders and as a tocolytic agent to prevent premature labour. We performed a metabolite profiling study in order to obtain a comprehensive picture of the constituents in B. pinnatum leaves and to identify chromatographic markers for quality control and safety assessment of medicinal preparations. Preliminary HPLC-PDA-ESIMS analyses revealed that flavonoid glycosides were the main UV-absorbing constituents in the MeOH extract of B. pinnatum. Two phenolic glucosides, syringic acid -D-glucopyranosyl ester (1) and 4′-O-D- glucopyranosyl-cis-p-coumaric acid (2), as well as nine flavonoids (3-11) including kaempferol, quercetin, myricetin, acacetin, and diosmetin glycosides were unambiguously identified by 1H and 2D NMR analysis after isolation from a MeOH extract. The flavonol glycosides quercetin 3-O-α-L-arabinopyranosyl-(1 → 2)-α-L-rhamnopyranoside 7-O-D-glucopyranoside (3) and myricetin 3-O-α-L-arabinopyranosyl-(1 → 2)-α-L-rhamnopyranoside (4) were new natural products. With the aid of HPLC-PDA-APCIMS and authentic references isolated from the related species B. daigremontianum, the presence of four bufadienolides, bersaldegenin-1-acetate (12), bryophyllin A (13), bersaldegenin-3-acetate (14), and bersaldegenin-1,3,5- orthoacetate (15) was detected in B. pinnatum. © Georg Thieme Verlag KG Stuttgart New York. Source


Background: Functional cardiovascular disorders (FCD) can be attributed to around 25-40% of all heart patients, i.e. organic causes are not detectable. Characteristic symptoms are tachycardia, palpitations, cardiac arrhythmia, hyperventilation, vertigo, vasovagal syncopes and sleep disorders, with the latter being a problem of its own. Disturbed vegetative rhythms form the basis of these diseases. The medicinal product Cardiodoron counteracts the dysfunctional vegetative rhythmicity with 3 medicinal plants - Primula veris (common cowslip), Hyoscyamus niger (black henbane) and Onopordum acanthium (cotton thistle). Patients and Methods: By means of a prospective, multicentre, non-interventional study, the development of disease-specific disorders during treatment with Cardiodoron (drops) was supposed to be shown. Between September 2009 and March 2012, 92 physicians documented 501 patients suffering from functional cardiovascular and/or sleep disorders who have been treated with Cardiodoron for 3-6 months. After an initial examination, a final examination after 90 (± 10) days and, in case of continuation of therapy, a follow-up examination after 90 (± 10) days were carried out. Besides 30 symptoms assessed by the physicians, the patients rated their condition on the basis of the complaints list according to v. Zerssen (B-L and B-L') and the Pittsburgh Sleep Quality Index (PSQI) according to Buysse. Results: The severity of functional cardiovascular disorders as well as sleep disorders was significantly reduced. The same applies for all of the documented 30 disease-specific symptoms. Furthermore, the total score of the complaints list was significantly reduced as well as the PSQI. The largest effect regarding all parameters was detectable after 3 months. Continuation of Cardiodoron therapy stabilised the symptomatology once more and resulted in further improvement. On average, patients reported initial improvement after 13 days of treatment. Tolerability was almost consistently assessed with 'very good / good'. Accordingly, the acceptance of the preparation by the patients was good, which resulted in a very good compliance of 70%. 52% of the patients used additional therapies. Conclusions: Cardiodoron shows positive effects in medical practice; it is a well-tolerated medicinal product for treatment of functional cardiovascular and/or sleep disorders with or without concomitant therapies. © 2013 S. Karger GmbH, Freiburg. Source

Discover hidden collaborations